5 accepted papers
Recent advances in $\textit{de novo}$ protein binder design have enabled increasing experimental validation, yet reported $\textit{in silico}$ metrics remain difficult to interpret or compare across studies due to non-standardized evaluation protocols. We introduce $\textbf{ProtDBench}$, a standardi…
Antibody design is crucial for developing therapies against diseases such as cancer and viral infections. Recent deep generative models have significantly advanced computational antibody design, particularly in enhancing binding affinity to target antigens. However, beyond binding affinity, antibodi…
Antibodies are central proteins in adaptive immune responses, responsible for protecting against viruses and other pathogens. Rational antibody design has proven effective in the diagnosis and treatment of various diseases like cancers and virus infections. While recent diffusion-based generative mo…
De novo protein design aims to create novel protein structures and sequences unseen in nature. Recent structure-oriented design methods typically employ a two-stage strategy, where structure design and sequence design modules are trained separately, and the backbone structures and sequences are gene…
Many crucial biological processes rely on networks of protein-protein interactions. Predicting the effect of amino acid mutations on protein-protein binding is important in protein engineering, including therapeutic discovery. However, the scarcity of annotated experimental data on binding energy po…